FedEx Delivery1–3 day delivery across the U.S.Free on orders over $200
Wolverine Stack, 10mg, lyophilized research peptide vial, Eppix Labs
Certificate of Analysis — 10mgCertificate of Analysis for Wolverine Stack 10mg
Chemical StructureWolverine Stack chemical structure
Amino Acid SequenceWolverine Stack amino acid chain
Latest COA1/2

BPC-157/TB-500 5mg/5mg

Janoshik

Batch BPCT-CA-26F-01

Result2026-06-29
Added2026-08-04
Avg Mass
BPC-157
6.25 mg
TB-500 (TB4)
5.86 mg
Verify on Janoshik
In StockBlends
BatchBPCT-CA-26F-01

Wolverine Stack - BPC 157 + TB-500

Recovery Compound

Also known as Wolverine Blend

BPC-157 – TB-500 Blend is a combination of two research peptides studied in laboratory settings for their potential roles in cellular signaling related to tissue repair, inflammation modulation, and recovery pathways. The combination is often explored for its complementary activity in peptide signaling studies.

$59.99USD
Purity VerifiedLab TestedSecure
Research Use Only

This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.

By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.

BPC-157 – TB-500 Blend, also known as the Wolverine Blend, is a dual-peptide research formulation combining BPC-157 and TB-500 in equal concentrations.

In scientific literature, BPC-157 is described as a synthetic fragment derived from a gastric protein sequence, while TB-500 is a synthetic form of thymosin beta-4. Together, they are studied in experimental models examining cellular response pathways, angiogenic signaling systems, and cytoskeletal dynamics under in vitro and preclinical research conditions.

Purity

Third-party tested for purity, ID, quantity.

Amino Acid Sequence
Amino acid chain diagram
Chemical Structure
Chemical structure diagram
BPC-157 Structure
Compound Properties
CAS Number137525-51-0
Molecular FormulaC62H98N16O22
Molecular Weight1419.5 g/mol
PubChem CID9941957
TB-500 Structure
Compound Properties
CAS Number77591-33-4
Molecular FormulaC212H350N56O78S
Molecular Weight4963.5 g/mol
PubChem CID16132341

Overview

BPC-157 and TB-500 have been independently examined in preclinical research environments. BPC-157 has been studied in models involving angiogenic signaling and connective tissue frameworks, while TB-500 has been evaluated in structural pathway and cellular migration research systems.

Within laboratory settings, the combined formulation is explored in experimental systems assessing coordinated peptide interaction across structural signaling pathways and cytoskeletal dynamics.

History

BPC-157 emerged from gastric peptide research in the early 1990s, while TB-500 research developed from investigations into thymosin beta-4 and its role in structural and cellular signaling pathways.

The BPC-157 – TB-500 Blend represents a research-based integration of these peptides into a unified formulation for controlled experimental study.

Key Research Areas

Laboratory investigations involving BPC-157 and TB-500 have explored structural pathway signaling, angiogenic models, and cellular migration frameworks. Experimental research examines peptide interaction within connective tissue systems and multi-pathway signaling environments under controlled in vitro and preclinical conditions.

2 of the 4 areas below are addressed directly by a paper cited on this page.

Structural and connective tissue signaling models

No paper cited on this page reports on structural, connective or tissue. This heading marks where Wolverine Stack is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.

Angiogenic pathway research

No paper cited on this page reports on angiogenic. This heading marks where Wolverine Stack is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.

Cellular migration and response systems

Addressed on this page by Chang 2011. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.

  • Chang, C.H. et al. (2011) The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985) 110(3):774–780.

Multi-peptide pathway interaction studies

Addressed on this page by Staresinic 2003, Chang 2011, Sikiric 2012. The work appeared in Curr Med Chem. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.

  • Staresinic, M. et al. (2003) Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.
  • Chang, C.H. et al. (2011) The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985) 110(3):774–780.
  • Sikiric, P. et al. (2012) Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem 19(1):126–132.

The references section of this page cites 6 primary papers published between 1999 and 2012 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.

Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Wolverine Stack, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.

Also called

Wolverine Stack is also referred to as BPC/TB stack, the healing stack, and technically as Wolverine Blend.

Preclinical only

Wolverine Stack is commonly described online in connection with faster healing from injury and improved recovery. In the research literature the same compound is filed under structural and connective tissue signaling models, angiogenic pathway research and cellular migration and response systems.

The 6 papers cited on this page, published between 1999 and 2012 (1 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.

Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.

Each strength of Wolverine Stack carries its own lot code and its own certificate — TBBP-CA-26E-01, BPCT-CA-26F-01 are separate tests, not one result applied across the range. The code printed on the vial you receive is the one to match, and matching it is what ties the material in hand to a test that was actually run on it.

Researchers who buy Wolverine Stack in the United States through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.

Verify a batch code →

Lyophilized storage
−20 °C long-term; stable at room temperature in transit
After reconstitution
2–8 °C
Light
Protect from UV and direct light
Freeze-thaw
Avoid repeated cycles
Vehicle
Bacteriostatic water in most published protocols
Format
Lyophilized powder

Wolverine Stack is a co-lyophilized blend — more than one compound freeze-dried together in a single vial. Handling follows the least stable component rather than an average, and the same is true of storage: the constraint that binds is whichever compound in the vial is most sensitive.

Reconstituting a blend does not separate its components, so a blend cannot be split into its parts after the fact. That is why per-component content verification matters more here than a single blended purity figure — the ratio inside the vial is fixed at manufacture and cannot be corrected downstream.

Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.

Reconstitution calculator →

Included
  • 1 × sealed glass vial in the strength selected (10mg / 1 Vial, 70mg / 1 Vial, 20mg / 1 Vial, 10mg / 5-Pack, 10mg / 10-Pack, 70mg / 5-Pack, 70mg / 10-Pack, 20mg / 5-Pack, 20mg / 10-Pack available), batch-labelled
  • The batch-linked Certificate of Analysis for the exact lot shipped
  • Discreet outer packaging with no product names on the exterior
  • FedEx, tracked, typically 1–3 business days domestically
Not included
  • Bacteriostatic water or any other reconstitution vehicle
  • Syringes, needles or filters
  • Dosing, administration or protocol guidance of any kind

Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.

No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.

Each vial contains 10mg of BPC-157 and 10mg of TB-500, totaling 20mg of lyophilized peptide blend. Independent third-party testing verifies purity, identity, and batch composition.

The vial contains only the lyophilized peptide blend. Any laboratory materials required for experimental procedures must be sourced separately.

Duration depends entirely on research protocol, storage conditions, and laboratory application.

Staresinic, M. et al.(2003)

Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.

PubMed
Chang, C.H. et al.(2011)

The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985) 110(3):774–780.

PubMed
Sikiric, P. et al.(2012)

Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem 19(1):126–132.

PubMed
Malinda, K.M. et al.(1999)

Thymosin beta4 accelerates wound healing.

PubMed
Smart, N. et al.(2007)

Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization.

PubMed
Guarnera, G. et al.(2010)

The effect of thymosin treatment of venous ulcers.

PubMed

Related

You May Also Like

Support

Need help?

Have questions about batch verification, documentation, or research specifications? Our team is available to assist with product and compliance inquiries.